As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan
As work continues on a new biologics plant in the U.S., Kyowa Kirin has completed the build out of another companion facility in its home country of Japan. The roughly $118-million plant in the city of Takasaki will make investigational drugs like antibodies for the company's early phase development efforts, Kyowa said.
As work continues on a new biologics plant in the U.S., Kyowa Kirin has completed the build out of another companion facility in its home country of Japan. The roughly $118-million plant in the city of Takasaki will make investigational drugs like antibodies for the company's early phase development efforts, Kyowa said.
